What are the most common mistakes with LL-37?
The most common LL-37 mistakes are treating it as a substitute for antibiotics (it's adjunct, not replacement); pushing dose in MCAS-prone users; skipping the cycle break. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for LL-37 is limited.
Common LL-37 mistakes
- Treating it as a substitute for antibiotics (it's adjunct, not replacement)
- Pushing dose in MCAS-prone users
- Skipping the cycle break
Bloodwork worth tracking
- CBC if running long courses
References
- LL-37, the truncation product of cathelicidin, antimicrobial review — Wang G, Curr Top Med Chem, 2020
- Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update — Svensson D et al., Inflammation Research, 2025
- Significance of the LL-37 Peptide Delivered from Human Cathelicidin in the Pathogenesis, Treatment, and Diagnosis of Sepsis — Mankowska A et al., Archivum Immunologiae et Therapiae Experimentalis, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on LL-37
Last updated 2026-06-15.